Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
Marsaud A, Dadone B, Ambrosetti D, Baudoin C, Chamorey E, Rouleau E, Lefol C, Roussel JF, Fabas T, Cristofari G, Carpentier X, Michiels JF, Amiel J, Pedeutour F. Marsaud A, et al. Among authors: ambrosetti d. Genes Chromosomes Cancer. 2015 Jun;54(6):369-82. doi: 10.1002/gcc.22248. Epub 2015 Mar 28. Genes Chromosomes Cancer. 2015. PMID: 25820192
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.
Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye PD, Mastri M, Moghrabi W, Cooley LS, Ettaiche M, Chamorey E, Parola J, Vial V, Lupu-Plesu M, Bernhard JC, Ravaud A, Borchiellini D, Ferrero JM, Bikfalvi A, Ebos JM, Khabar KS, Grépin R, Pagès G. Dufies M, et al. Among authors: ambrosetti d. Cancer Res. 2017 Mar 1;77(5):1212-1226. doi: 10.1158/0008-5472.CAN-16-3088. Epub 2017 Jan 13. Cancer Res. 2017. PMID: 28087600
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G. Dufies M, et al. Among authors: ambrosetti d. Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29. Br J Cancer. 2017. PMID: 28850564 Free PMC article. Clinical Trial.
Sirtuin 7: a new marker of aggressiveness in prostate cancer.
Haider R, Massa F, Kaminski L, Clavel S, Djabari Z, Robert G, Laurent K, Michiels JF, Durand M, Ricci JE, Tanti JF, Bost F, Ambrosetti D. Haider R, et al. Among authors: ambrosetti d. Oncotarget. 2017 Aug 24;8(44):77309-77316. doi: 10.18632/oncotarget.20468. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100388 Free PMC article.
Comprehensive study of three novel cases of TFEB-amplified renal cell carcinoma and review of the literature: Evidence for a specific entity with poor outcome.
Mendel L, Ambrosetti D, Bodokh Y, Ngo-Mai M, Durand M, Simbsler-Michel C, Delhorbe M, Amiel J, Pedeutour F. Mendel L, et al. Among authors: ambrosetti d. Genes Chromosomes Cancer. 2018 Mar;57(3):99-113. doi: 10.1002/gcc.22513. Epub 2017 Dec 20. Genes Chromosomes Cancer. 2018. PMID: 29127730 Review.
120 results